Quotient To Perform Development and Testing for MediGene

Quotient Clinical, a business unit of Quotient Bioresearch, will work with MediGene AG to undertake a RapidFACT formulation development and clinical testing program on MediGene’s RhuDex, subject to ethical and Medicines and Healthcare products Regulatory Agency (MHRA) approval. Rhudex is a new potential first-in-class treatment for rheumatoid arthritis and other inflammatory disorders.

Quotient Clinical’s RapidFACT service leverages its integrated GMP manufacturing and clinical testing processes and facilities to enable rapid clinical evaluation of new drug formulations. According to Quotient, compared to conventional development processes, RapidFACT enables shortening of project timelines, and a reduction of 90% in API consumption, delivering significant cost savings. MediGene will use the drug formulation selected in this program as the basis for the further clinical development of RhuDex.

Mark Egerton, M.D., managing director of Quotient Clinical, commented, “We are delighted to be working with MediGene to advance RhuDex to the next stage of clinical development. RapidFACT has now been employed across a wide selection of development projects, and we have secured strong data to validate the time and cost savings benefits that can be delivered to development project teams.”